Subtotal $0.00
Shop Now
“Peptides for muscle growth” usually refers to a group of compounds promoted online to build muscle or speed recovery: growth hormone secretagogues such as CJC-1295, ipamorelin, sermorelin and tesamorelin, growth hormone-releasing peptides (GHRPs), IGF-1 LR3, follistatin and the so-called recovery peptides BPC-157 and TB-500. None of them is FDA-approved for building muscle. For most, published human research is small, short or absent, the FDA has raised specific safety concerns, and all are prohibited in sport. This guide explains what each group is, what the evidence actually measured and where each compound stands legally in 2026.
Key Takeaways
- No peptide is FDA-approved to increase muscle size or strength in healthy people.
- Most human studies of these compounds measured hormone levels, not muscle or strength.
- In a 2008 review of trials in young, fit adults, growth hormone itself raised lean body mass but did not appear to improve strength.
- The FDA has cited immunogenicity, impurities and serious adverse events for several of these peptides.
- All of them are on the WADA 2026 Prohibited List, most in class S2.
What people mean by peptides for muscle growth
Peptides are short chains of amino acids, the building blocks of proteins. Our guide to what peptides are covers the basics. The compounds marketed for muscle fall into five rough groups:
- GHRH analogs: lab-made versions of growth hormone-releasing hormone, including sermorelin, CJC-1295 and tesamorelin.
- Ghrelin mimetics and GHRPs: peptides that act on the ghrelin receptor, such as ipamorelin, GHRP-2 and GHRP-6. Some are sold together, as in the CJC-1295 and ipamorelin blend.
- IGF-1 analogs: mainly IGF-1 LR3, a modified form of insulin-like growth factor 1.
- Myostatin blockers: follistatin-344, a form of a natural protein that binds myostatin.
- Recovery peptides: BPC-157 and TB-500, promoted for tendon, ligament and muscle recovery rather than growth.
How these compounds are supposed to work
Most of them target the growth hormone axis. The hypothalamus releases growth hormone-releasing hormone (GHRH), the pituitary gland responds by releasing growth hormone, and growth hormone signals the liver and other tissues to make insulin-like growth factor 1 (IGF-1). GHRH analogs act at the first step and ghrelin mimetics at a parallel receptor on the pituitary, so both depend on the body’s own growth hormone release. IGF-1 LR3 skips the chain and copies the end signal.
Follistatin works differently. Myostatin is a signal that limits muscle growth, and animals without working myostatin develop much larger muscles. Follistatin binds myostatin and blocks it. A plausible mechanism is not proof of an effect in people, which is why the human evidence below matters.
What the human evidence shows
Growth hormone itself
The strongest data concern growth hormone (somatropin), not the peptides. A 2008 systematic review in the Annals of Internal Medicine pooled randomized trials covering 303 young, physically fit adults given growth hormone. Lean body mass rose by about 2.1 kg compared with controls, but strength and exercise capacity did not seem to improve, and people on growth hormone more often had soft tissue swelling and fatigue. The authors concluded that claims of better physical performance were not supported. A 2007 review by the same group, covering 220 healthy older adults, found small changes in body composition along with more swelling, joint pain, carpal tunnel syndrome and breast tissue growth in men.
Secretagogue peptides
For the secretagogues, human studies mostly measured hormones. Two 2006 trials of CJC-1295 in healthy adults found growth hormone levels rose 2- to 10-fold and IGF-1 levels 1.5- to 3-fold, but they did not test muscle or strength. Ipamorelin’s main trial was in 117 adults recovering from bowel surgery, and it did not reach its goal. GHRP-2 has been used mainly as a diagnostic test of the pituitary. Tesamorelin’s approval trials measured deep abdominal fat in adults with HIV, and its label says it is not indicated for weight loss. We found no published controlled trial showing that any of these peptides builds muscle or strength in healthy adults.
IGF-1 LR3, follistatin, BPC-157 and TB-500
We found no published clinical trial of IGF-1 LR3 in people. The main human follistatin research tested a gene therapy, not the protein sold online, in six men with Becker muscular dystrophy. A 2025 systematic review of BPC-157 in musculoskeletal medicine found 36 studies, of which 35 were in cells or animals. For TB-500, the FDA stated it had not identified any human exposure data.
Regulatory status of peptides for muscle growth
| Compound | Type | FDA status | Compounding status (2026) | WADA 2026 |
|---|---|---|---|---|
| Somatropin (growth hormone) | 191-amino-acid protein | Rx for labeled conditions such as GH deficiency | Distribution for other uses is a federal crime | S2 |
| Tesamorelin | GHRH analog | Rx (Egrifta) for abdominal fat in HIV lipodystrophy | Compounded versions are not FDA-approved | S2 |
| Sermorelin | GHRH analog | Formerly approved (Geref, discontinued) | Not in Category 2; compounded versions not FDA-approved | S2 |
| CJC-1295 | GHRH analog | Not approved | Out of Category 2; not eligible for 503A compounding | S2 |
| Ipamorelin | Ghrelin mimetic | Not approved | Advisory committee voted 12-0 against (2024) | S2 |
| GHRP-2, GHRP-6 | GHRPs | Not approved | Category 3 (nominated without adequate support) | S2 |
| IGF-1 LR3 | IGF-1 analog | Not approved | Not on the 503A bulks list | S2 |
| Follistatin-344 | Myostatin-binding protein | Not approved | Not in any 503A category | S4 |
| BPC-157 | Synthetic 15-amino-acid peptide | Not approved | Out of Category 2 (April 2026); July 2026 vote pending FDA action | S0 |
| TB-500 | Thymosin beta-4 fragment | Not approved | Out of Category 2 (April 2026); July 2026 vote pending FDA action | S2 |
Two 2026 events cause confusion. On April 15, 2026, the FDA removed BPC-157, TB-500 and ten other peptides from Category 2, its list of bulk substances that raise significant safety risks in compounding, because the nominations were withdrawn. That did not make them eligible for compounding. On July 23 and 24, 2026, the FDA’s Pharmacy Compounding Advisory Committee voted to recommend six peptides, including BPC-157 and TB-500, for the 503A bulks list, while FDA staff opposed them. The vote is advisory, and as of late September 2026 the FDA had not added them. Our guide on whether peptides are legal explains these lists.
FDA safety concerns
When the FDA reviewed several of these peptides for compounding, it cited a possible risk of immunogenicity (an unwanted immune response), problems with peptide impurities and limited safety information. For CJC-1295 it listed serious adverse events including increased heart rate and a body-wide widening of blood vessels. For ipamorelin it cited a published study reporting serious adverse events, including death, when the peptide was given intravenously.
Products sold online as research chemicals add another layer of risk. In an August 24, 2026 warning letter to one online seller whose products included tesamorelin, the FDA said that despite “research use” labeling, the products were intended to be drugs for human use, and it warned that products given with a needle bypass some of the body’s key defenses against toxins and microorganisms. Nobody checks such products for identity, purity or sterility before sale.
Approved growth hormone products carry their own label warnings, including tumors (neoplasms), impaired glucose tolerance and diabetes, raised pressure inside the skull and fluid retention. The tesamorelin label warns that it raises IGF-1 and that the long-term effects of this are unknown.
Sport and the WADA 2026 list
The World Anti-Doping Agency’s 2026 Prohibited List bans growth hormone, GHRH analogs such as CJC-1295, sermorelin and tesamorelin, secretagogues such as ipamorelin, GHRPs, IGF-1 and its analogues, and thymosin beta-4 derivatives such as TB-500 under class S2. Follistatin is banned under S4 as a myostatin-binding protein, and BPC-157 under S0 as a non-approved substance. All are prohibited at all times, in and out of competition.
The approved contexts
A few related medicines are FDA-approved for narrow, diagnosed conditions. Somatropin is a prescription protein for children and adults with growth hormone deficiency and several other labeled conditions. Tesamorelin (Egrifta) is approved only to reduce excess abdominal fat in adults with HIV who have lipodystrophy. Mecasermin (Increlex), a copy of natural IGF-1, is approved for children with severe primary IGF-1 deficiency. None of these approvals covers muscle building in healthy people, and using growth hormone outside its approved uses is illegal to distribute.
If you are concerned about muscle loss, weakness or low hormone levels, a licensed healthcare provider can test for real causes and explain approved options. For other peptide topics, see our guide to peptides for weight loss or the full Peptide Guide.
Frequently Asked Questions
Do peptides for muscle growth work?
There is no good evidence that they build muscle or strength in healthy people. Most human studies measured hormone levels, and several compounds have no published human trials at all.
Are any peptides FDA-approved for muscle growth?
No. Tesamorelin is approved only for abdominal fat in adults with HIV lipodystrophy, and somatropin only for growth hormone deficiency and other labeled conditions.
Is BPC-157 legal now?
It is still not FDA-approved. It left the Category 2 list in April 2026 and an advisory committee voted for it in July 2026, but the FDA had not added it to the compounding list as of late September 2026.
Are these peptides banned in sport?
Yes. The WADA 2026 list prohibits all of them at all times, mostly in class S2, with follistatin in S4 and BPC-157 in S0.
What are the risks of research peptides?
The FDA has cited immune reactions, impurities and serious adverse events. Research-labeled products are not checked for identity, purity or sterility.
Does growth hormone build muscle?
In trials of young, fit adults it raised lean body mass by about 2 kg but did not appear to improve strength or exercise capacity, and side effects were more common.
This article is general information, not medical or legal advice. Peptide Labs does not sell prescription, investigational or unapproved peptides, including any compound named here. Ask a licensed healthcare provider or pharmacist how this information applies to you.
Last reviewed September 2026.
Related guides: HGH Peptides vs HGH: What Growth Hormone Peptides Really Are, Are Peptides Steroids? Peptides vs Steroids Explained, Are Peptides Safe? Side Effects and Risks by Type of Peptide, Tesamorelin vs Sermorelin: FDA Status, Mechanism and What the Evidence Shows.